Back to Search
PATRICK BEDARD MD
MD
Emergency Medicine Physician
NPI: 1396246823IndividualAccepts Medicare
Specialties, Licenses & Credentials
General Practice Physician
General Practice
Code: 208D00000X
32008(NE)
Emergency Medicine PhysicianPrimary
Emergency Medicine
Code: 207P00000X
32008(NE)
Education
OTHER
Class of 2018
Research & Publications (20)
Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer.
PMID 19275756·Curr Cancer Drug Targets·2009
6-review
International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy.
PMID 19657108·J Natl Cancer Inst·2009
6-review
Are we HER-ting for innovation in neoadjuvant breast cancer trial design?
PMID 19216727·Breast Cancer Res·2009
6-review
Stemming resistance to HER-2 targeted therapy.
PMID 19259796·J Mammary Gland Biol Neoplasia·2009
6-review
Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?
PMID 19418111·Target Oncol·2009
6-review
Progress in tailoring adjuvant endocrine therapy for postmenopausal women with early breast cancer.
PMID 19593135·Curr Opin Oncol·2009
6-review
Sowing the soil for cure? Results of the ABCSG-12 trial open a new chapter in the evolving adjuvant bisphosphonate story in early breast cancer.
PMID 19652062·J Clin Oncol·2009
7-preclinical
Current paradigms for the use of HER2-targeted therapy in early-stage breast cancer.
PMID 19158036·Clin Breast Cancer·2008
6-review
Characterization of the novel P-selectin inhibitor PSI-697 [2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h] quinoline-4-carboxylic acid] in vitro and in rodent models of vascular inflammation and thrombosis.
PMID 18024786·J Pharmacol Exp Ther·2008
4-observational
Matters of the heart: cardiac toxicity of adjuvant systemic therapy for early-stage breast cancer.
PMID 18231644·Curr Oncol·2008
8-other
Prophylactic P-selectin inhibition with PSI-421 promotes resolution of venous thrombosis without anticoagulation.
PMID 18278184·Thromb Haemost·2008
4-observational
Overcoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer?
PMID 18351454·Breast Cancer Res Treat·2008
6-review
Recent advances in adjuvant systemic therapy for early-stage breast cancer.
PMID 18611869·Ann Oncol·2008
6-review
Nonhormonal systemic therapy for advanced breast cancer: do the math!
PMID 19066269·J Natl Cancer Inst·2008
8-other
Statistical power of negative randomized controlled trials presented at American Society for Clinical Oncology annual meetings.
PMID 17687153·J Clin Oncol·2007
8-other
Resolution of venous thrombosis using a novel oral small-molecule inhibitor of P-selectin (PSI-697) without anticoagulation.
PMID 17334507·Thromb Haemost·2007
4-observational
Transfer of follow-up care to family physicians for early-stage breast cancer.
PMID 17359902·Clin Oncol (R Coll Radiol)·2007
8-other
The impact of patient-prosthesis mismatch on late outcomes after mitral valve replacement.
PMID 17532940·J Thorac Cardiovasc Surg·2007
8-other
Synthesis and biological evaluation of quinoline salicylic acids as P-selectin antagonists.
PMID 17201408·J Med Chem·2007
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 9040 FITZSIMMONS DR
JOINT BASE LEWIS MCCHORD, WA 98431 - Phone
- (253) 968-2997
Quick Facts
- NPI
- 1396246823
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 8
- Publications
- 20
Are you this provider?
Claim Your Profile